Table 4.

Univariates analyses of risk factors for recurrence during the first three posttransplant years

Factors	HR	95 % CI	p
Serum AFP concentration	1.40a	1.20–1.63	<0.001
Size of the largest tumor	1.48b	1.20–1.83	<0.001
No. of tumors	1.21c	1.03–1.41	0.017
Total tumor volume	1.03d	1.01–1.05	0.001
Microvascular invasion	1.95	0.63–6.04	0.248
Poor tumor differentiation	2.63	0.54–12.71	0.230
Bilateral tumors	0.70	0.19–2.54	0.586
Neoadjuvant therapy	1.50	0.49–4.62	0.479
Salvage liver transplantation	2.69	0.59–12.20	0.200
Incidental tumors	0.70	0.09–5.40	0.734
Tumors beyond Milan criteria	4.55	1.25–16.67	0.022
Tumors beyond UCSF criteria	2.54	0.85–7.58	0.095
Tumors beyond Up-to-7 criteria	3.64	1.22–10.87	0.021
Recipient age	0.62e	0.39–0.99	0.044
Recipient sex	0.76f	0.23–2.45	0.641
Child-Turcotte-Pugh class C	1.10	0.21–5.67	0.913
Model for end-stage liver disease	1.03g	0.94–1.12	0.561
Hepatitis C virus infection	0.95	0.31–2.91	0.931
Hepatitis B virus infection	1.39	0.47–4.14	0.555
Alcoholic cirrhosis	1.01	0.22–4.56	0.996
Donor age	0.76e	0.50–1.16	0.202
Donor sex	0.23f	0.08–0.69	0.009
Cold ischemia	1.45h	0.84–2.52	0.187
Conventional technique for liver transplantation	4.99	1.68–14.87	0.004
Packed RBC transfusions	0.95i	0.78–1.15	0.569
FFP transfusions	0.86i	0.66–1.11	0.236
Total operative time	1.16h	0.75–1.80	0.503
Duration of hepatectomy	0.63h	0.247–1.62	0.340
Warm ischemia	1.05j	0.85–1.29	0.662

HR hazard ratio, CI confidence interval

^aincrease by 100 ng/ml

^bIncrease by 1 cm

^cIncrease by 1 tumor

^dIncrease by 10 cm³

^eIncrease by 10 years

^fMale sex

^gIncrease by 1 point

^hIncrease by 1 h

ⁱIncrease by 1 unit

^jIncrease by 10 min